Slide 1: Excelling in strategy execution
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices
Slide 2: Q1 2022 Results
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Q1 2022 Results Play to Win April 28, 2022
Slide 3: Forward-looking statements
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward- looking statements are statements that a
Slide 4: Agenda
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Agenda 01 Excelling in strategy execution Paul Hudson, John Reed 02 Business update Bill Sibold, Thomas Triomphe, Olivier Charmeil & Julie van Ongevalle 03 Financial performance Jean-Baptiste de Chatillon 0
Slide 5: Excelling in strategy execution
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Excelling in strategy execution
Slide 6: Q1 2022 high single-digit sales growth, +8.6%
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Q1 2022 high single-digit sales growth, +8.6% Specialty Care Vaccines GenMed Dupixent® up 45.7% €3.6bn €1.0bn €3.8bn +17.8% +6.8% -0.7% Vaccines delivered again in Q1 Core assets GenMed core assets up ~5% C
Slide 7: Constant improvement of profitability while investing in R&D
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Constant improvement of profitability while investing in R&D Q1 2019 Q1 2020 Q1 2021 Q1 2022 Sales growth 4.2% 6.6% 2.4% 8.6% R&D spend (€m) 1,385 1,340 1,267 1,489 BOI margin 27.3%1 29.6%1 30.7% 31.7% EPS
Slide 8: Dupixent blazing the trail for immunology leadership
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Dupixent blazing the trail for immunology leadership ® Dermatology Respiratory Gastroenterology Atopic Dermatitis Asthma COPD EoE or UC ® ® ® Type 2 Injectables - amlitelimab (anti-OX40L) - amlitelimab (ant
Slide 9: R&D collaborations continually replenishing the pipeline
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D collaborations continually replenishing the pipeline Sarclisa IgM ADCs AI SubQ antibody Funding development of a Exclusive collaboration Leveraging Exscientia’s Discover agonists subcutaneous formulatio
Slide 10: Tackling the challenge of pediatric cancer trials
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Tackling the challenge of pediatric cancer trials together with leading oncology institutions Innovating for vulnerable communities Design of clinical trials in the pediatric cancer setting is challenging d
Slide 11: Progressing an innovative oncology portfolio
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Progressing an innovative oncology portfolio 2022 2023 2024 Update on key oncology programs Sarclisa IKEMA 2L mPFS o Sarclisa - Launch momentum expected to be boosted by additional data readouts IMROZ 1L MM
Slide 12: SAR444245: A differentiated IL-2 engineered for specificity and selectivity
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices SAR444245: A differentiated IL-2 engineered for specificity and selectivity SAR444245 NKTR-214 Engineered SAR’245 has potential for: Single, targeted PEG-moiety 6 random PEG irreversibly linked to nAA, moit
Slide 13: Q1 pipeline milestones in areas of high unmet need
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Q1 pipeline milestones in areas of high unmet need Approvals Dupixent® Asthma EU 6- to 11-year-old children Xenpozyme® ASMD Japan SAKIGAKE EnjaymoTM CAD US Priority Review Filings Dupixent® AD infant US Pri
Slide 14: Business update
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Business update Q1 2022
Slide 15: Specialty Care performance €3.6bn sales
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Specialty Care performance €3.6bn sales +17.8% Q1 2022 Dupixent® Oncology Dupixent® Outstanding performance with ~430k patients on €244m €1,614m therapy ac
Slide 16: Dupixent
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent ® More than €500m in incremental quarterly sales over prior year Global Dupixent® sales (€m) Outstanding performance in Q1 Ex-US US Worldwide grow
Slide 17: Dupixent leading in Type 2 inflammatory diseases
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Dupixent leading in Type 2 inflammatory diseases ® Leading with Dermatologist Weekly Leading with Allergist Weekly Leading with Pulmonologist Weekly NBRx N
Slide 18: Expanding leadership in rare diseases
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Expanding leadership in rare diseases Continued growth driven by New product launches new launches - Establishing a new standard of Patient accruals sustai
Slide 19: Vaccines performance €1bn sales
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Vaccines performance €1bn sales +6.8% Q1 2022 Travel & Endemics Polio Pertussis Hib PPH driven by strong Pentaxim® €613m performance in China €98m +61.0% +
Slide 20: Nirsevimab, all infant protection against RSV
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare Nirsevimab, all infant protection against RSV Pivotal trial results published in NEJM1 74.5% 77.3% Efficacy compared Reduction of RSV- to placebo associate
Slide 21: GenMed performance €3.8bn sales
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed performance €3.8bn sales -0.7% Q1 2022 Core Core assets assets Double-digit growth for Transplant portfolio, Multaq® , Praluent® and Soliqua® €1,594
Slide 22: GenMed: Q1 2022 core asset performance
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare GenMed: Q1 2022 core asset performance € millions -8.2% +6.3% 0% +39.4% 401 377 274 261 253 251 196 +13.9% +21.41% 132 +15.9% 72 87 56 69 53 44 Lovenox Tou
Slide 23: CHC: Growing in line with market
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC: Growing in line with market Growth (MAT, in %) Performance driven by strategy execution +13.5% +12.0% 1 Cut & embrace complexity +7.8% 2 Reinforce our
Slide 24: CHC performance €1.3bn sales
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Specialty Care Vaccines GenMed Consumer Healthcare CHC performance €1.3bn sales +17.0% Q1 2022 Digestive Wellness Pain Care 3 drivers €325m €314m Execution of our strategic priorities +13.8% 24% 24% +22.5%
Slide 25: Financial performance
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Financial performance Q1 2022
Slide 26: Q1 P&L
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Q1 P&L €m Q1 2022 Q1 2021 % Change (CER) Net Sales 9,674 8,591 +8.6% Other revenues 379 295 +23.7% Gross profit 7,175 6,202 +11.1% Gross margin % 74.2% 72.2% R&D (1,489) (1,267) +14.0% SG&A (2,379) (2,194)
Slide 27: Value creation through EUROAPI spin-off
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Value creation through EUROAPI spin-off Create a world leader in APIs in Europe EUROAPI Ordinary dividend growth Additional dividend in kind and worldwide ~58% of Impact on 2022 BOI margin slightly accretiv
Slide 28: Sanofi pioneers sustainable finance in the pharma sector
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Sanofi pioneers sustainable finance in the pharma sector Committed to integrating sustainability within Play to Win strategy and investment and financing strategy March 2022 Sustainability-Linked Bond The c
Slide 29: Outlook 2022
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Outlook 2022
Slide 30: 2022 business outlook
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices 2022 business outlook Sales Specialty Care Vaccines Growth driven by Dupixent®, Record flu season sales P&L N&I slightly down, all other franchises growing Gross margin improvement due to product mix and ef
Slide 31: Reaffirmed 2022 FY guidance
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Reaffirmed 2022 FY guidance BOI margin EPS growth 30% Low double-digit growth at CER Approximately +4% to +5% currency impact1 Barring unforseen events. 1. Based on April 2022 average rates. 31 Investor Rel
Slide 32: Planned events
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Planned events ESG event Hemophilia event July 5 July 13 32 Investor Relations
Slide 33: Q&A session
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices Q&A session
Slide 34: R&D appendices
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D appendices
Slide 35: Expected R&D milestones in 2022
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected R&D milestones in 2022 H1 2022 Comment H2 2022 Dupixent® EoE US/EU regulatory submissions Achieved US PN US/EU regula
Slide 36: R&D Pipeline Phase III & Registration
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline Phase III & Registration Phase III Registration Name Description Indication Name Description Indication Dupixent®
Slide 37: R&D Pipeline – Phase II
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase II Phase II Name Description Indication Name Description Indication R Kevzara®A Anti-IL-6 mAb Polyarticul
Slide 38: R&D Pipeline – Phase I
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations R&D Pipeline – Phase I Phase I Name Description Indication SAR441566 Oral TNF inhibitor Inflammatory indications SAR444656I,1
Slide 39: Expected submission timelines
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Expected submission timelines 2022 2023 2024 2025 and beyond Sarclisa® Kevzara®A Kevzara®A Dupixent®A Dupixent®A Dupixent ®A t
Slide 40: COVID-19 recombinant vaccine program
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations COVID-19 recombinant vaccine program 1 Phase 3 Safety & Efficacy Trial – primary vaccine (event-driven) Monovalent Final Stage
Slide 41: Financial appendices
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Financial appendices
Slide 42: Q1 sales and EPS
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Q1 sales and EPS Currency impact Company sales Business EPS €341m +0.07 +0.04 225 -0.15 -0.12 -0.15 -0.11 0 0 -0.11 -480 -0.15
Slide 43: Net debt evolution in Q1 2022
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Net debt evolution in Q1 20221 in € 9,983 9,432 -27 360 -1,998 361 1,100 -347 Net Debt FCF before Proceeds Asset Restructuring
Slide 44: 2022 currency sensitivity and Q1 2022 currency exposure
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations 2022 currency sensitivity and Q1 2022 currency exposure 2022 Business EPS currency sensitivity Currency exposure on Q1 2022 sa
Slide 45: Main product sales
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Main product sales Q1 2022 sales (€m) Growth Dupixent 1,614 45.7% Lantus 671 -1.5% Aubagio 491 -6.6% Lovenox 377 -8.2% Plavix
Slide 46: Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi accounting of Antibody License and Collaboration Agreement with Regeneron 1 Last updated September 2021 US Ex-US Net sa
Slide 47: Sanofi Libtayo accounting pursuant to Regeneron agreement
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi Libtayo® accounting pursuant to immuno-oncology License and Collaboration Agreement with Regeneron 1,2 Last updated Sep
Slide 48: ESG appendices
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations ESG appendices
Slide 49: Sanofi ESG Q1 achievements
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q1 achievements Affordable access Innovating for vulnerable communities Global Health Unit #Patients treated Vials
Slide 50: Sanofi ESG Q1 achievements
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG Q1 achievements Healthy Planet Inclusive workplace Blister-free vaccines Scope 1 & 2 Diverse Senior Leadership Stre
Slide 51: Sanofi ESG ratings
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Sanofi ESG ratings Rating agencies SCORE Climate 22 B 4.2/5 3.47/5 92% 62/100 86/100 86/100 A Change: A Medium risk Water: A N
Slide 52: Collaborations
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Collaborations Ref Name Developed in collaboration with… A Dupixent® Regeneron itepekimab Libtayo® Kevzara® B efanesoctocog al
Slide 53: Abbreviations
Excelling in strategy execution Business update Financial performance Outlook 2022 Appendices R&D appendices Financial appendices ESG appendices Collaborations Abbreviations Abbreviations ACIP Advisory Committee on Immunization GAA Acid Alpha-Glucosidase PD-1 Programmed cell Death protein 1 Practice